臨床婦人科産科59巻11号

2005年11月発行

今月の臨床 婦人科の新しい画像診断法─PETを中心として

ポジトロンエミッショントモグラフィ（PET） 臨床での位置づけ 婦人科領域での有用化 悪性腫瘍診断における展望

婦人科がんの術前評価

著者： 蝦名康彦¹ 櫻木範明¹

所属機関： ¹北海道大学大学院医学研究科生殖発達医学講座婦人科学分野

ページ範囲：P.1482 - P.1487

文献概要

はじめに

　FDG─PET（以下，PET）を用いた婦人科悪性腫瘍の診断においては，子宮体癌に関する報告はほとんどないため，本稿では子宮頸癌と卵巣癌の診断について，自験例と報告例をまとめながら，最新の知見について概説したい．

参考文献

1） Sakuragi N, Satoh C, Takeda N, et al : Incidence and distribution pattern of pelvic and paraaortic lymph node metastasis in patients with Stages IB, IIA, and IIB cervical carcinoma treated with radical hysterectomy. Cancer 85 : 1547─1554, 1999

2） Rose PG, Adler LP, Rodriguez M, et al : Positron emission tomography for evaluating para─aortic nodal metastasis in locally advanced cervical cancer before surgical staging : a surgicopathologic study. J Clin Oncol 17 : 41─45, 1999

3） Reinhardt MJ, Ehritt─Braun C, Vogelgesang D, et al : Metastatic lymph nodes in patients with cervical cancer : detection with MR imaging and FDG PET. Radiology 218 : 776─782, 2001

4） Belhocine T, Thille A, Fridman V, et al : Contribution of whole─body 18FDG PET imaging in the management of cervical cancer. Gynecol Oncol 87 : 90─97, 2002

5） Narayan K, Hicks RJ, Jobling T, et al : A comparison of MRI and PET scanning in surgically staged loco─regionally advanced cervical cancer : potential impact on treatment. Int J Gynecol Cancer 11 : 263─271, 2001

6） Roh JW, Seo SS, Lee S, et al : Role of positron emission tomography in pretreatment lymph node staging of uterine cervical cancer : a prospective surgicopathologic correlation study. Eur J Cancer 41 : 2086─2092, 2005

7） Havrilesky LJ, Kulasingam SL, Matchar DB, et al : FDG─PET for management of cervical and ovarian cancer（review）．Gynecol Oncol 97 : 183─191, 2005

8） Sugawara Y, Eisbruch A, Kosuda S, et al : Evaluation of FDG PET in patients with cervical cancer. J Nucl Med 40 : 1125─1131, 1999

9） Yeh LS, Hung YC, Shen YY, et al : Detecting para─aortic lymph nodal metastasis by positron emission tomography of 18F─fluorodeoxyglucose in advanced cervical cancer with negative magnetic resonance imaging findings. Oncol Rep 9 : 1289─1292, 2002

10） Tran BN, Grigsby PW, Dehdashti F, et al : Occult supraclavicular lymph node metastasis identified by FDG─PET in patients with carcinoma of the uterine cervix. Gynecol Oncol 90 : 572─576, 2003

11） Grigsby PW, Siegel BA, Dehdashti F : Lymph node staging by positron emission tomography in patients with carcinoma of the cervix. J Clin Oncol 19 : 3745─3749, 2001

12） Grigsby PW, Siegel BA, Dehdashti F, et al : Posttherapy［18F］fluorodeoxyglucose positron emission tomography in carcinoma of the cervix : response and outcome. J Clin Oncol 22 : 2167─2171, 2004

13） Hubner KF, McDonald TW, Niethammer JG, et al : Assessment of primary and metastatic ovarian cancer by positron emission tomography（PET）using 2─［18F］deoxyglucose（2─［18F］FDG）．Gynecol Oncol 51 : 197─204, 1993

14） Schroder W, Zimny M, Rudlowski C, et al : The role of 18F─fluoro─deoxyglucose positron emission tomography（18F─FDG PET）in diagnosis of ovarian cancer. J Gynecol Cancer 9 : 117─122, 1999

15） Fenchel S, Grab D, Nuessle K, et al : Asymptomatic adnexal masses : correlation of FDG PET and histopathologic findings. Radiology 223 : 780─788, 2002

16） Yoshida Y, Kurokawa T, Kawahara K, et al : Incremental benefits of FDG positron emission tomography over CT alone for the preoperative staging of ovarian cancer. Am J Roentgenol 182 : 227─233, 2004

17） Karlan BY, Hawkins R, Hoh C, et al : Whole─body positron emission tomography with 2─［18F］─fluoro─2─deoxy─D─glucose can detect recurrent ovarian carcinoma. Gynecol Oncol 51 : 175─181, 1993

18） Rose PG, Faulhaber P, Miraldi F, et al : Positive emission tomography for evaluating a complete clinical response in patients with ovarian or peritoneal carcinoma : correlation with second─look laparotomy. Gynecol Oncol 82 : 17─21, 2001

19） Zimny M, Siggelkow W, Schroder W, et al : 2─［Fluorine─18］─fluoro─2─deoxy─d─glucose positron emission tomography in the diagnosis of recurrent ovarian cancer. Gynecol Oncol 83 : 310─315, 2001

20） Sijmons EA, Heintz AP : Second─look and second surgery : second chance or second best？．Semin Surg Oncol 19 : 54─61, 2000

21） Ebina Y, Akashi D, Takeda M, et al : 18F─fluoro─deoxyglucose positron emission tomography for the detection of recurrent ovarian cancer. PET and Molecular Imaging, State of the art and future perspectives. International Congress Series 1264, pp222─226, Elsevier, Netherlands, 2004

22） Zimny M : PET and PET─CT in oncology. pp 227─235. Springer, Belrin, 2004

23） Menzel C, Dobert N, Hamscho N, et al : The influence of CA 125 and CEA levels on the results of（18）F─deoxyglucose positron emission tomography in suspected recurrence of epithelial ovarian cancer. Strahlenther Onkol 180 : 497─501, 2004

24） Avril N, Sassen S, Schmalfeldt B, et al : Prediction of response to neoadjuvant chemotherapy by sequential F─18─fluorodeoxyglucose positron emission tomography in patients with advanced─stage ovarian cancer. J Clin Oncol Sep 19, 2005［Epub ahead of print］

25） Lerman H, Metser U, Grisaru D, et al : Normal and abnormal 18F─FDG endometrial and ovarian uptake in pre─ and postmenopausal patients : assessment by PET／CT. Nucl Med 45 : 266─271, 2004